Information Provided By: 
Fly News Breaks for June 14, 2019
MNK
Jun 14, 2019 | 07:17 EDT
Canaccord analyst Dewey Steadman lowered his price target on Mallinckrodt to $22 from $37 following the company's release of a blinded RA study showing Acthar's effectiveness. The analyst noted the data is the first of a string of expected Acthar data reads that he thinks can bolster and justify Acthar's use for exacerbations in highly refractory immune-modulated conditions. The price target reduction is based on a lower expected contribution from pipeline products. Steadman maintained his Buy rating on Mallinckrodt shares.
News For MNK From the Last 2 Days
There are no results for your query MNK
